Article open access publication

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Cancer Research, American Association for Cancer Research (AACR), ISSN 0008-5472

Volume 77, 17, 2017

DOI:10.1158/0008-5472.can-16-3172, Dimensions: pub.1090389747, PMID: 28655789,

Affiliations

Organisations

  1. (1) Herlev Hospital, grid.411900.d, Capital Region
  2. (2) Copenhagen University Hospital, grid.4973.9, Capital Region
  3. (3) Lund University, grid.4514.4
  4. (4) Antoni van Leeuwenhoek Hospital, grid.430814.a
  5. (5) University of Gothenburg, grid.8761.8
  6. (6) Martin Luther University Halle-Wittenberg, grid.9018.0
  7. (7) University of Catania, grid.8158.4
  8. (8) Aarhus University Hospital, grid.154185.c, Central Denmark Region

Countries

Denmark

Netherlands

Italy

Germany

Sweden

Continents

Europe

Description

Cancer immunotherapy can result in durable tumor regressions in some patients. However, patients who initially respond often experience tumor progression. Here, we report mechanistic evidence of tumoral immune escape in an exemplary clinical case: a patient with metastatic melanoma who developed disease recurrence following an initial, unequivocal radiologic complete regression after T-cell-based immunotherapy. Functional cytotoxic T-cell responses, including responses to one mutant neoantigen, were amplified effectively with therapy and generated durable immunologic memory. However, these immune responses, including apparently effective surveillance of the tumor mutanome, did not prevent recurrence. Alterations of the MHC class I antigen-processing and presentation machinery (APM) in resistant cancer cells, but not antigen loss or impaired IFNγ signaling, led to impaired recognition by tumor-specific CD8+ T cells. Our results suggest that future immunotherapy combinations should take into account targeting cancer cells with intact and impaired MHC class I-related APM. Loss of target antigens or impaired IFNγ signaling does not appear to be mandatory for tumor relapse after a complete radiologic regression. Personalized studies to uncover mechanisms leading to disease recurrence within each individual patient are warranted. Cancer Res; 77(17); 4562-6. ©2017 AACR.

Funders

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

Aarhus University

Dimensions Citation Indicators

Times Cited: 19

Field Citation Ratio (FCR): 5.08

Relative Citation ratio (RCR): 0.84

Open Access Info

Bronze